Table 2.
Affinities relative to hu3F8-IgG1*
| Affinity for CD16 | Affinity for CD32 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibody | FcR | n | Relative to hu3F8-IgG1 on CD16A(158F) | SD | P value | FcR | n | Relative to hu3F8-IgG1 on CD32A(131R) | SD | P value | A:I Ratioˆ |
| hu3F8-IgG1 | CD16A(158V) | 3 | 3 | 0.2 | 0.001 | CD32A(131R) | 3 | 1.0** | 0.1 | 9 | |
| CD16A(158F) | 3 | 1** | 0.1 | CD32A(131H) | 3 | 1.3** | 0.1 | 0.01 | |||
| CD16B | 3 | 1** | 0.2 | CD32B | 3 | 0.3** | 0.0 | ||||
| hu3F8-IgG1n | CD16A(158V) | 4 | 11 | 1.7 | 0.002 | CD32A(131R) | 4 | 0.5** | 0.1 | 0.01 | 35 |
| CD16A(158F) | 4 | 4 | 0.7 | 0.002 | CD32A(131H) | 4 | 0.6** | 0.1 | 0.003 | ||
| CD16B | 4 | 2** | 0.1 | 0.01 | CD32B | 4 | 0.3** | 0.1 | NS | ||
| hu3F8-IgG1-DEL | CD16A(158V) | 3 | 25 | 5 | 0.01 | CD32A(131R) | 3 | 1.4** | 0.1 | 0.01 | 18 |
| CD16A(158F) | 3 | 16 | 3 | 0.01 | CD32A(131H) | 3 | 1.3** | 0.2 | NS | ||
| CD16B | 3 | 15 | 1 | 0.002 | CD32B | 3 | 1.4** | 0.3 | 0.02 | ||
| hu3F8-IgG1n-DEL | CD16A(158V) | 6 | 63 | 16 | 0.0002 | CD32A(131R) | 4 | 0.3** | 0.1 | 0.003 | 165 |
| CD16A(158F) | 6 | 37 | 9 | 0.0002 | CD32A(131H) | 4 | 0.3** | 0.2 | 0.0002 | ||
| CD16B | 6 | 14 | 4 | 0.0004 | CD32B | 4 | 0.4** | 0.1 | NS | ||
*
Affinity reference highlighted in grey.
**
These results were fitted with steady-state equilibrium analysis as noted in the footnote of Table 1. All others were fitted with Two-State Reaction.
ˆ
A:I ratio = Activating: inhibitory = (relative KA on CD16-158V)/(relative KA on CD32B).